Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
, 45 (8), 794-807

Molecular Targeted Therapy for Advanced Hepatocellular Carcinoma: Current Status and Future Perspectives

Affiliations
Review

Molecular Targeted Therapy for Advanced Hepatocellular Carcinoma: Current Status and Future Perspectives

Ying-Chun Shen et al. J Gastroenterol.

Abstract

Sorafenib, a multikinase inhibitor targeting vascular endothelial growth factor (VEGF)-mediated angiogenesis, is the first drug found to prolong survival of patients with advanced hepatocellular carcinoma (HCC). This advance has shifted the paradigm of systemic treatment for HCC toward molecular targeted therapy (MTT). However, the disease-stabilizing effect of VEGF signaling-targeted MTT normally lasts only for a few months, suggesting a rapid emergence of resistance in the majority of patients. To overcome the resistance to VEGF signaling-targeted MTT, strategies incorporating inhibition of either compensatory pro-angiogenic pathways or recruitment of bone marrow-derived circulating endothelial progenitors, as well as suppression of other oncogenic pathways, are currently being investigated. The combination of multiple molecular targeted agents or the use of multi-target agents may enhance the efficacy at the expense of increased toxicities. To facilitate the development of MTT for HCC, current methodologies for pharmacodynamic assessment, patient selection and target identification need to be improved. Patient selection according to the individual molecular signature of the tumor and correlative biomarker studies are encouraged while planning a clinical trial of novel MTT.

Similar articles

See all similar articles

Cited by 24 articles

See all "Cited by" articles

References

    1. Acta Oncol. 2007;46(2):234-8 - PubMed
    1. J Clin Oncol. 2009 Apr 10;27(11):1800-5 - PubMed
    1. Cancer Cell. 2005 Oct;8(4):299-309 - PubMed
    1. Liver. 1999 Apr;19(2):151-9 - PubMed
    1. Lancet Oncol. 2009 Nov;10(11):1111-8 - PubMed

MeSH terms

Feedback